Rasagiline as Adjunct to Levodopa for Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis

Table 1

Characteristics of studies included.

Study	Study duration, weeks	N	Male, n (%)	Age, years^a	PD duration, years^a	Baseline levodopa dosage, mg/day^a
Zhang, 2018 [30]	16	R/L: 163; L: 158	R/L: 103 (63.2); L: 109 (69.0)	R/L: 62.7; L: 61.7	R/L: 7.4^b; L: 7.1^b	R/L: 501.0^b; L: 550.0^b
Hattori, 2018 [24]	26	R/L: 129; L: 141	R/L: 46 (35.7); L: 53 (37.6)	R/L: 65.8; L: 66.3	R/L: 9.5; L: 8.9	R/L: 421.0; L: 399.3
Hauser, 2015 [32]	12	R/L: 154 L: 155	R/L: 95 (61.7); L: 78 (50.3)	R/L: 63.6; L: 63.0	R/L: 8.3^c; L: 8.2^c	R/L: 800.0^c; L: 650.0^c
Zhang, 2013 [31]	12	R/L: 119; L: 125	R/L: 64 (53.8); L: 67 (53.6)	R/L: 61.6; L: 61.6	R/L: 5.6; L: 5.4	R/L: 515.0; L: 521.0
Rascol, 2005 [18]	18	R/L: 231; L: 229	R/L: 154 (66.7); L: 132 (57.6)	R/L: 63.9; L: 64.8	R/L: 8.7; L: 8.8	R/L: 722.0; L: 697.0^d
Parkinson Study Group, 2005 [17]	26	R/L: 149; L: 159	R/L: 99 (66.4); L: 104 (65.4)	R/L: 62.; L: 64.5	R/L: 8.8; L: 9.7	R/L: 815.0; L: 821.0

^aAll values are means unless otherwise indicated ^bNot explicitly reported in publication but assumed to be mean ^cMedian. ^dNot explicitly reported in publication but assumed to be daily levodopa dose (mg/day). L, levodopa; PD, Parkinson’s disease; R/L, rasagiline/levodopa combination therapy.